A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and Luigi Naldini, has unveiled a powerful strategy to rejuvenate the ...

B7-H3–directed CAR T-cell therapy showed safety and tolerability in recurrent glioblastoma patients, with no dose-limiting toxicities or severe adverse effects observed. The study achieved a 44% ...

With a five-year survival rate of less than 5%, glioblastoma is one of the most aggressive types of brain cancer. Until now, all available treatments, including immunotherapy - which involves ...

CHICAGO -- Intracerebroventricular (ICV) delivery of bivalent CAR T-cells targeting EGFR and IL13Rα2 was feasible and appeared safe in patients with recurrent glioblastoma (GBM) in a phase I study ...

Researchers designed CAR T cells that locally release VEGF-blocking molecules, weakening tumor defenses and boosting immune ...

Left: UMAP projections of CD8⁺/WPRE⁺ (adoptive T cells) and CD8⁺/WPRE⁻ (endogenous T cells) cells mapped onto a reference TIL atlas reveal a reduced prevalence of exhausted CD8⁺ T cells and enrichment ...

Glioblastoma (GBM), the most aggressive primary brain tumor, continues to portend a poor prognosis with median survival under two years, despite standard care involving surgery, radiation, and ...

Glioblastoma is the most frequent and aggressive primary brain cancer in adults, and patients can expect to live shorter than 2 years, regardless of therapy. The cancer can be treated with CAR T cells ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells that dramatically prolongs their effectiveness after being infused into ...

The MarketWatch News Department was not involved in the creation of this content. In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved ...

In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting ...